Studies: AstraZeneca, Boehringer drugs beat older blood thinners

08/30/2009 | Los Angeles Times (tiered subscription model)

AstraZeneca's Brilinta and Boehringer Ingelheim's Pradaxa outperformed blood thinners Plavix and warfarin in reducing the risk of clots, heart attack, stroke and death, according to studies presented at the European Society of Cardiology Congress in Spain. AstraZeneca is awaiting FDA approval for Brilinta, while Boehringer sells Pradaxa in 40 countries.

View Full Article in:

Los Angeles Times (tiered subscription model)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Senior Counsel – Regulatory Affairs
RAI Services Company
Winston-Salem, NC